Phathom Pharmaceuticals (PHAT) Change in Accured Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Change in Accured Expenses for 9 consecutive years, with $23.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 89.04% year-over-year to $23.4 million; the TTM figure through Jun 2026 stood at $49.0 million (up 33.5% YoY), while the FY2025 annual figure was $34.1 million, down 2.38% from the prior year.
• Change in Accured Expenses improved to $23.4 million in Q2 2026 per PHAT's latest filing, from -$3.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $27.6 million in Q4 2025 and bottomed at -$11.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $5.8 million across 5 years, with a median of $4.3 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 2517.9% — and 2025, when it slumped 90.16%.
• Phathom Pharmaceuticals' Change in Accured Expenses stood at $3.9 million in 2022, then jumped by 162.11% to $10.3 million in 2023, then soared by 94.24% to $19.9 million in 2024, then jumped by 38.26% to $27.6 million in 2025, then decreased by 15.14% to $23.4 million in 2026.
• Business Quant data shows PHAT's Change in Accured Expenses at $23.4 million in Q2 2026, -$3.1 million in Q1 2026, and $27.6 million in Q4 2025.